160 related articles for article (PubMed ID: 21273063)
1. Design of potent and selective GPR119 agonists for type II diabetes.
Szewczyk JW; Acton J; Adams AD; Chicchi G; Freeman S; Howard AD; Huang Y; Li C; Meinke PT; Mosely R; Murphy E; Samuel R; Santini C; Yang M; Zhang Y; Zhao K; Wood HB
Bioorg Med Chem Lett; 2011 May; 21(9):2665-9. PubMed ID: 21273063
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
3. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
4. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
[TBL] [Abstract][Full Text] [Related]
8. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
Herbert MR; Siegel DL; Staszewski L; Cayanan C; Banerjee U; Dhamija S; Anderson J; Fan A; Wang L; Rix P; Shiau AK; Rao TS; Noble SA; Heyman RA; Bischoff E; Guha M; Kabakibi A; Pinkerton AB
Bioorg Med Chem Lett; 2010 Oct; 20(19):5718-21. PubMed ID: 20801037
[TBL] [Abstract][Full Text] [Related]
11. 2,5-Disubstituted pyridines as potent GPR119 agonists.
Wu Y; Kuntz JD; Carpenter AJ; Fang J; Sauls HR; Gomez DJ; Ammala C; Xu Y; Hart S; Tadepalli S
Bioorg Med Chem Lett; 2010 Apr; 20(8):2577-81. PubMed ID: 20227877
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
13. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
Sato H; Macchiarulo A; Thomas C; Gioiello A; Une M; Hofmann AF; Saladin R; Schoonjans K; Pellicciari R; Auwerx J
J Med Chem; 2008 Mar; 51(6):1831-41. PubMed ID: 18307294
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
15. Isochromanone-based urotensin-II receptor agonists.
Lehmann F; Currier EA; Olsson R; Hacksell U; Luthman K
Bioorg Med Chem; 2005 Apr; 13(8):3057-68. PubMed ID: 15781415
[TBL] [Abstract][Full Text] [Related]
16. Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.
Azimioara M; Alper P; Cow C; Mutnick D; Nikulin V; Lelais G; Mecom J; McNeill M; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessl T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 Dec; 24(23):5478-83. PubMed ID: 25455488
[TBL] [Abstract][Full Text] [Related]
17. Discovery of phenyl acetamides as potent and selective GPR119 agonists.
Zhu C; Wang L; Zhu Y; Guo ZZ; Liu P; Hu Z; Szewczyk JW; Kang L; Chicchi G; Ehrhardt A; Woods A; Seo T; Woods M; van Heek M; Dingley KH; Pang J; Salituro GM; Powell J; Terebetski JL; Hornak V; Campeau LC; Orr RK; Ujjainwalla F; Miller M; Stamford A; Wood HB; Kowalski T; Nargund RP; Edmondson SD
Bioorg Med Chem Lett; 2017 Mar; 27(5):1124-1128. PubMed ID: 28185720
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists.
Budzik BW; Evans KA; Wisnoski DD; Jin J; Rivero RA; Szewczyk GR; Jayawickreme C; Moncol DL; Yu H
Bioorg Med Chem Lett; 2010 Feb; 20(4):1363-7. PubMed ID: 20097073
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Oda K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
Bioorg Med Chem Lett; 2016 Aug; 26(15):3441-6. PubMed ID: 27390068
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.
Fang Y; Xu J; Li Z; Yang Z; Xiong L; Jin Y; Wang Q; Xie S; Zhu W; Chang S
Bioorg Med Chem; 2018 Aug; 26(14):4080-4087. PubMed ID: 30100020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
